Biopacific Partners

What Biopacific Partners does

BioPacific Partners is a privately-held life science consultancy headquartered in Auckland, New Zealand, that acts as a two-sided bridge between Australia/New Zealand innovation sources and global multinational demand. Founded in 2003 originally as BioPacific Ventures (a specialist venture fund in food, agriculture and health) and re-cast in 2014 as a fee-for-service consultancy, the firm operates from a single Auckland office (Suite 105, Formery East, 87 Albert Street) with a core team of eight science-and-business bilingual professionals (Executive Directors, Principal Consultants, Senior Consultants, an Analyst, and an Office Manager) supported by an advisory bench of 13+ senior industry figures from GSK, Monsanto, Nestlé, Bristol Myers Squibb, Abbott Nutrition, and Procter & Gamble.

The firm's service portfolio covers the full commercialization continuum: Search and Evaluation (scouting ANZ innovations for global clients), Innovation Landscapes (competitor, KOL, and opportunity analysis), Securing Innovation (deal-making including licensing, collaboration, equity investment, and acquisition), Transaction Services (local deal management and due diligence), Project Management (on-the-ground oversight of contracted research), Local Representation (ongoing ANZ partner for multinational corporates), and a co-funded Beyond IP intangible asset advisory programme delivered in partnership with Callaghan Innovation. A monthly free Whiteboard Sessions community motion serves as the top-of-funnel channel targeting ANZ startups and technology transfer offices. Documented engagements include facilitation of US$300M+ in cumulative deal value, a 36-technology landscape for a Top 5 pharmaceutical company, identification of 13 new application areas for a publicly-listed medtech firm (which subsequently tripled in value), and capital raises (NZ$2.8M for a functional beverage company; NZ$600K seed for a botanical drug venture).

Revenue is generated through professional services engagements — search and evaluation, advisory retainers, transaction success fees, and programme-specific fees (Beyond IP engagements are co-funded, up to 40% to a NZ$10,000 cap). Pricing is quote-based, tailored to engagement scope, and contracts run on multi-year cadences. Customer segments split between Multinational Corporates (the primary revenue base, including Top 5 pharma and Top 5 consumer health), ANZ start-ups and growth-stage companies, established ANZ firms seeking international partnerships, universities and research institutes needing commercialization support, and public-sector/government advisory work. The firm has no digital self-serve or marketplace products and generates demand entirely through relationship-driven direct engagement, industry-association access (Ausbiotech, NZBIO, KiwiNet), case-study marketing, and the Whiteboard Sessions community motion.

Name

Biopacific Partners

Legal name

BioPacific Partners Limited

Website

https://biopacificpartners.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

BioPacific Partners is an Auckland-based life science consultancy that scouts, evaluates, and commercializes Australia/New Zealand innovations for global multinational clients, and advises ANZ companies on commercialization and capital raising across pharma, biotech, medtech, agritech, food, and consumer health sectors.

Ownership category

akta.pro rank

Headquarters

HQ city

Auckland

HQ country

New Zealand

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Consulting and Advisory Services: Professional services revenue generated through consultancy engagements including search and evaluation, innovation landscapes, deal securing, transaction services, project management, governance advisory, and strategic planning. Services are tailored to client growth stage and delivered by experienced life science professionals.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

BioPacific Partners is a life science consultancy that helps global companies identify, evaluate, and acquire innovations from Australia and New Zealand, while assisting ANZ innovators with commercialization, deal-making, and international market access. Core services include search and evaluation, innovation landscapes, securing innovation (deal-making), transaction services, project management, local representation, and the Beyond IP intangible asset management programme.

Product overview

BioPacific Partners is a life science consultancy, not a software product company. The company offers a unified set of advisory and deal-making services centered around connecting Australian and New Zealand life science innovations to global markets. Services include Search and Evaluation, Innovation Landscapes, Securing Innovation, Transaction Services, Project Management, Local Representation, Whiteboard Sessions (free monthly brainstorming sessions), and Beyond IP (intangible asset management programme). These services are delivered by a team of science and business bilingual consultants and supported by industry advisors.

Differentiator

Problem solved

Functional benefit

Products and services

• Search and Evaluation Scouting and evaluation of world-class life science innovations from Australian and New Zealand universities, research institutes, start-ups, and mature companies for global corporate clients looking to strengthen their pipelines.
• Innovation Landscapes Comprehensive research and analysis of the life sciences, health, food, and agriculture industries, including landscape reviews, competitor analysis, identification of key opinion leaders, and opportunity assessments for global clients.
• Securing Innovation Professional deal-making service that secures valuable additions to client pipelines, including collaboration, licensing, material supply, equity investment, and acquisition.
• Transaction Services Local management of the deal process in ANZ, including local intelligence, deal team support, technical due diligence, and commercial intelligence, to help clients close deals.
• Project Management Local presence and quality control for multinational clients' collaborative or contracted research projects in ANZ, including troubleshooting and ensuring projects stay on track.
• Local Representation Local ANZ representation for multinational clients, facilitating deal-flow, management of local assets, or governance of partnerships with hands-on guidance.
• Beyond IP (Intangible Asset Management Programme) Tailored 12-month programme co-funded by Callaghan Innovation that helps growth companies maximise the value of their intangible asset portfolio, including proprietary data, staff expertise, and customer relationships; Callaghan Innovation covers up to 40% of costs up to NZ $10,000.

Named customers9 records

Segments6 records

Ideal customer profiles6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Callaghan InnovationcoreStrategic or Co-development PartnerBioPacific Partners is an approved provider of Callaghan Innovation's 'Beyond IP' intangible asset management programme for New Zealand businesses. The Beyond IP programme is co-funded by Callaghan Innovation, which covers up to 40% of participating companies' programme costs up to a maximum of $10,000. BioPacific specializes in helping growth companies maximize the value of their intangible asset portfolios as part of this programme.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Accenture Life Sciences: Large consulting and technology services firm with a dedicated Life Sciences practice serving global pharma and consumer health clients across innovation, R&D, and commercial functions. Represents scale competition for enterprise search-and-evaluation mandates.
• Charles River Associates: Global consulting firm with a Life Sciences practice providing strategy, litigation, and transaction advice to pharma, biotech, and medtech. Broader portfolio but meaningful overlap in deal advisory and market intelligence work.
• McKinsey Life Sciences Practice: Global strategy consulting firm's life sciences practice advising top global pharma and consumer health companies on innovation sourcing, R&D strategy, and M&A. Competes for the same Top 5 enterprise mandates as BioPacific.
• ZS Associates: Global consulting firm focused on life sciences and healthcare, with strengths in commercialization, sales, and innovation strategy. Operates at much larger scale but targets overlapping pharma/consumer health mandates.
• L.E.K. Consulting: Global management consulting firm with a substantial Life Sciences practice covering strategy, M&A, and innovation sourcing for pharma/biotech. A larger incumbent that competes for the same enterprise mandates.

Direct peers

• Health Advances: Healthcare and life sciences strategy consulting firm supporting medtech, pharma, and diagnostics companies with commercialization, M&A, and partnership strategy. Strong functional overlap with BioPacific's innovation landscapes and securing innovation.
• PharmaVentures: Global pharma advisory and transaction firm specializing in deal-making, licensing, M&A, and strategic partnering. Mirrors BioPacific's transaction services and Securing Innovation offerings.
• Alacrita Consulting: Boutique life sciences consulting firm offering commercial, due diligence, and strategic advisory to pharma, biotech, and medtech clients. Comparable in size and service mix to BioPacific Partners.
• Catenion: Biopharma-focused strategy consulting firm combining scientific depth with commercial advisory. Comparable science-to-business translation capability for global pharma and biotech clients.
• Novateur Ventures: Life sciences innovation scouting and commercialization advisory firm connecting global pharma/biotech with regional innovators. Closest analogue in business model and core offering, though anchored in North America rather than ANZ.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/biopacpartners

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biopacific Partners